The European markets have recently seen a resurgence, with the pan-European STOXX Europe 600 Index climbing 3.93% over a week, buoyed by the European Central Bank's interest rate cuts and easing trade tensions. While larger indices capture much of the spotlight, penny stocks offer a unique investment avenue that can still yield significant growth opportunities. Despite being considered niche and somewhat outdated, these smaller or newer companies can provide an attractive mix of affordability and potential when they demonstrate strong financial health.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Bredband2 i Skandinavien (OM:BRE2) | SEK2.12 | SEK2.03B | ✅ 4 ⚠️ 0 View Analysis > |
| Transferator (NGM:TRAN A) | SEK2.69 | SEK249.54M | ✅ 2 ⚠️ 3 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.63 | SEK272.2M | ✅ 4 ⚠️ 3 View Analysis > |
| Hifab Group (OM:HIFA B) | SEK3.64 | SEK222.67M | ✅ 2 ⚠️ 2 View Analysis > |
| IMS (WSE:IMS) | PLN3.60 | PLN122.02M | ✅ 3 ⚠️ 2 View Analysis > |
| FAE Technology (BIT:FAE) | €2.30 | €46.06M | ✅ 4 ⚠️ 3 View Analysis > |
| Cellularline (BIT:CELL) | €2.53 | €53.36M | ✅ 4 ⚠️ 2 View Analysis > |
| Netgem (ENXTPA:ALNTG) | €0.95 | €31.81M | ✅ 4 ⚠️ 3 View Analysis > |
| Arcure (ENXTPA:ALCUR) | €4.01 | €23.22M | ✅ 3 ⚠️ 3 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.185 | €301.67M | ✅ 3 ⚠️ 1 View Analysis > |
Click here to see the full list of 431 stocks from our European Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Cellectis (ENXTPA:ALCLS)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Cellectis S.A. is a clinical-stage biotechnology company focused on developing gene-editing products, particularly allogeneic chimeric antigen receptor T-cells, with a market cap of €99.92 million.
Operations: The company's revenue is primarily generated from its Therapeutics segment, amounting to $49.22 million.
Market Cap: €99.92M
Cellectis S.A., a clinical-stage biotechnology company, has shown significant revenue growth with full-year sales reaching US$41.51 million, up from US$0.755 million the previous year. Despite being unprofitable, Cellectis has reduced its net loss to US$36.76 million from US$101.06 million and maintains a strong financial position with short-term assets of $287.1M exceeding liabilities and more cash than total debt. The company benefits from an experienced management team and board, offering stability amidst high share price volatility common in penny stocks while actively participating in industry conferences to enhance visibility and partnerships.
- Unlock comprehensive insights into our analysis of Cellectis stock in this financial health report.
- Evaluate Cellectis' prospects by accessing our earnings growth report.
Hunter Group (OB:HUNT)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Hunter Group ASA is an investment company that primarily focuses on shipping and oil service investments in Norway and internationally, with a market cap of NOK140.20 million.
Operations: The company's revenue segment is primarily derived from developing and operating Very Large Crude Carriers (VLCCs), with reported revenues of -$8.29 million.
Market Cap: NOK140.2M
Hunter Group ASA is currently pre-revenue with reported negative sales of US$8.3 million and a net loss of US$11.87 million for the year ended December 31, 2024. Despite its unprofitable status, the company benefits from having no debt and short-term assets of $7.8 million that cover both its short and long-term liabilities. The management team is well-seasoned with an average tenure of 6.9 years, although the board's tenure suggests recent changes which may affect strategic direction. Share price volatility remains high compared to Norwegian peers, reflecting typical penny stock characteristics in Europe.
- Dive into the specifics of Hunter Group here with our thorough balance sheet health report.
- Review our historical performance report to gain insights into Hunter Group's track record.
Precise Biometrics (OM:PREC)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Precise Biometrics AB (publ) provides identification software for secure identity authentication across Sweden, Taiwan, Denmark, Finland, Norway, and internationally with a market cap of SEK327.93 million.
Operations: The company generates revenue from two main segments: Digital Identity, contributing SEK21.43 million, and Biometric Technologies, accounting for SEK65.42 million.
Market Cap: SEK327.93M
Precise Biometrics AB, with a market cap of SEK327.93 million, operates in the biometric technology space with two main revenue streams: Digital Identity and Biometric Technologies. Despite being unprofitable, the company has seen its revenues grow modestly, reporting SEK21.79 million for Q4 2024. It remains debt-free and covers its liabilities comfortably with short-term assets of SEK67.7 million. Recent strategic moves include expanding sales into Norway to meet growing demand for its visitor management system and integrating BioLive into India's Aadhaar program, enhancing security against biometric spoofing threats—key developments that could bolster future growth prospects amidst high share price volatility typical of penny stocks.
- Click to explore a detailed breakdown of our findings in Precise Biometrics' financial health report.
- Learn about Precise Biometrics' future growth trajectory here.
Turning Ideas Into Actions
- Investigate our full lineup of 431 European Penny Stocks right here.
- Want To Explore Some Alternatives? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Hunter Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com